Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.32

+2.7%

Jan 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (10407)	2/12/2004 9:58:45 AM
From: Biomaven	Read Replies (1) of 52153

The last figure I saw was $800m from Tufts. That included the cost of capital and the cost of failed drugs. Certainly the biotechs don't spend anything like this - my guess is that $400m is closer to the mark. Of course a lot depends on the particular drug - it's a lot cheaper with a weird orphan indication where your total trials population is under 100 than it is for an anti-depressant or the like with total trials population approaching 10,000. As to who is to blame, that is a hard question. I've often wondered what would happen if some small technically advanced country (someplace like Singapore or Israel) offered a "safety only" regime where new drugs could be sold once minimal safety had been demonstrated (no requirement that efficacy be demonstrated). This would be an intermediate position between the US regulation of drugs (very tough) and nutritional supplements (very lax). Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next